Journal of Southern Medical University ›› 2026, Vol. 46 ›› Issue (9): 2222-2229.doi: 10.12122/j.issn.1673-4254.2026.09.20
Juanjuan ZHANG1, Shuhuan YAO2, Zuyuan ZHAO3, Xiang SUN2, Ziyin ZHU2, Li LI2,4(
), Haitao WEI4(
)
Received:2026-01-26
Online:2026-09-20
Published:2026-09-30
Contact:
Li LI, Haitao WEI
E-mail:10210051@vip.henu.edu.cn;taoge9885@163.com
Juanjuan ZHANG, Shuhuan YAO, Zuyuan ZHAO, Xiang SUN, Ziyin ZHU, Li LI, Haitao WEI. Effects of Baduanjin, bedside cycle ergometer and balloon-blowing training on pulmonary function recovery following thoracoscopic surgery for lung cancer: a randomized controlled trial[J]. Journal of Southern Medical University, 2026, 46(9): 2222-2229.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.j-smu.com/EN/10.12122/j.issn.1673-4254.2026.09.20
| Variable | Baduanjin group (n=108) | Bedside cycle ergometer training group (n=109) | Balloon-blowing training group (n=117) | χ2/F | P |
|---|---|---|---|---|---|
| Age (year) | 63.20±8.14 | 62.71±7.86 | 63.84±7.51 | 0.643 | 0.526 |
| Gender (n) | 0.331 | 0.847 | |||
| Male | 61 | 59 | 68 | ||
| Female | 47 | 50 | 49 | ||
| BMI | 23.40±3.03 | 23.08±2.82 | 23.55±3.05 | 0.712 | 0.491 |
| Education level | 1.926 | 0.382 | |||
| High school or below | 65 | 70 | 76 | ||
| Junior college or above | 43 | 39 | 41 | ||
| Disease characteristics | |||||
| Disease course (years) | 5.21±2.12 | 4.92±2.25 | 5.40±2.05 | 1.245 | 0.289 |
| Pathological type | 0.894 | 0.925 | |||
| Squamous cell carcinoma | 31 | 29 | 35 | ||
| Adenocarcinoma | 72 | 75 | 77 | ||
| Other | 5 | 5 | 5 | ||
| Clinical stage | 1.557 | 0.817 | |||
| I | 71 | 74 | 75 | ||
| II | 31 | 29 | 35 | ||
| IIIa | 6 | 6 | 7 | ||
| Comorbidities | |||||
| Hypertension | 39 | 35 | 45 | 1.025 | 0.599 |
| Diabetes mellitus | 19 | 16 | 22 | 0.752 | 0.686 |
| Coronary heart disease | 11 | 9 | 13 | 0.522 | 0.770 |
| Smoking history | 0.385 | 0.825 | |||
| Yes | 57 | 62 | 63 | ||
| No | 51 | 47 | 54 | ||
| Surgery-related indicators | |||||
| Surgical method | 0.288 | 0.866 | |||
| Lobectomy | 90 | 92 | 99 | ||
| Segmentectomy | 18 | 17 | 18 | ||
| Operation time (min) | 89.83±5.22 | 88.50±6.06 | 90.11±4.99 | 0.412 | 0.663 |
| Intraoperative blood loss (mL) | 41.76±8.71 | 40.20±9.27 | 42.57±8.11 | 1.283 | 0.278 |
| Postoperative 24-hour drainage volume (mL) | 35.20±9.11 | 33.82±8.72 | 33.80±8.74 | 1.967 | 0.142 |
| Chest tube duration (days) | 1.56±0.53 | 1.57±0.64 | 1.77±0.40 | 1.445 | 0.237 |
| Postoperative hospital stay (days) | 3.61±1.15 | 3.52±1.16 | 3.83±0.99 | 2.342 | 0.098 |
Tab.1 Comparison of general clinical data among the 3 groups of patients
| Variable | Baduanjin group (n=108) | Bedside cycle ergometer training group (n=109) | Balloon-blowing training group (n=117) | χ2/F | P |
|---|---|---|---|---|---|
| Age (year) | 63.20±8.14 | 62.71±7.86 | 63.84±7.51 | 0.643 | 0.526 |
| Gender (n) | 0.331 | 0.847 | |||
| Male | 61 | 59 | 68 | ||
| Female | 47 | 50 | 49 | ||
| BMI | 23.40±3.03 | 23.08±2.82 | 23.55±3.05 | 0.712 | 0.491 |
| Education level | 1.926 | 0.382 | |||
| High school or below | 65 | 70 | 76 | ||
| Junior college or above | 43 | 39 | 41 | ||
| Disease characteristics | |||||
| Disease course (years) | 5.21±2.12 | 4.92±2.25 | 5.40±2.05 | 1.245 | 0.289 |
| Pathological type | 0.894 | 0.925 | |||
| Squamous cell carcinoma | 31 | 29 | 35 | ||
| Adenocarcinoma | 72 | 75 | 77 | ||
| Other | 5 | 5 | 5 | ||
| Clinical stage | 1.557 | 0.817 | |||
| I | 71 | 74 | 75 | ||
| II | 31 | 29 | 35 | ||
| IIIa | 6 | 6 | 7 | ||
| Comorbidities | |||||
| Hypertension | 39 | 35 | 45 | 1.025 | 0.599 |
| Diabetes mellitus | 19 | 16 | 22 | 0.752 | 0.686 |
| Coronary heart disease | 11 | 9 | 13 | 0.522 | 0.770 |
| Smoking history | 0.385 | 0.825 | |||
| Yes | 57 | 62 | 63 | ||
| No | 51 | 47 | 54 | ||
| Surgery-related indicators | |||||
| Surgical method | 0.288 | 0.866 | |||
| Lobectomy | 90 | 92 | 99 | ||
| Segmentectomy | 18 | 17 | 18 | ||
| Operation time (min) | 89.83±5.22 | 88.50±6.06 | 90.11±4.99 | 0.412 | 0.663 |
| Intraoperative blood loss (mL) | 41.76±8.71 | 40.20±9.27 | 42.57±8.11 | 1.283 | 0.278 |
| Postoperative 24-hour drainage volume (mL) | 35.20±9.11 | 33.82±8.72 | 33.80±8.74 | 1.967 | 0.142 |
| Chest tube duration (days) | 1.56±0.53 | 1.57±0.64 | 1.77±0.40 | 1.445 | 0.237 |
| Postoperative hospital stay (days) | 3.61±1.15 | 3.52±1.16 | 3.83±0.99 | 2.342 | 0.098 |
| Time point/Variable | Baduanjin group (n=108) | Bedside cycle ergometer training group (n=109) | Balloon-blowing training group (n=117) | F | P |
|---|---|---|---|---|---|
| Postoperative day 1 | |||||
| FEV1 (L) | 1.52±0.31 | 1.49±0.33 | 1.51±0.32 | 0.21 | 0.812 |
| FVC (L) | 2.18±0.41 | 2.15±0.43 | 2.17±0.42 | 0.15 | 0.861 |
| FEV1/FVC (%) | 69.81±5.20 | 69.33±5.52 | 69.60±5.29 | 0.24 | 0.787 |
| Postoperative 4 weeks | |||||
| FEV1 (L) | 1.78±0.33 | 1.85±0.35* | 1.71±0.32 | 4.12 | 0.017 |
| FVC (L) | 2.52±0.45 | 2.58±0.47 | 2.48±0.44 | 1.45 | 0.236 |
| FEV1/FVC (%) | 70.62±4.81 | 71.70±5.11* | 68.94±4.92 | 3.78 | 0.024 |
| Postoperative 12 weeks | |||||
| FEV1 (L) | 2.05±0.38* | 2.15±0.40* | 1.92±0.36 | 9.85 | <0.001 |
| FVC (L) | 2.85±0.50 | 2.91±0.52 | 2.79±0.49 | 1.92 | 0.148 |
| FEV1/FVC (%) | 71.90±4.51* | 73.79±4.70* | 68.84±4.62 | 12.34 | <0.001 |
| Postoperative six months | |||||
| FEV1 (L) | 2.11±0.39* | 2.21±0.41* | 1.98±0.37 | 8.15 | <0.001 |
| FVC (L) | 2.90±0.51 | 2.96±0.53 | 2.85±0.50 | 1.79 | 0.168 |
| FEV1/FVC (%) | 72.82±4.41* | 74.50±4.63* | 69.52±4.48 | 12.28 | <0.001 |
| Postoperative one year | |||||
| FEV1 (L) | 2.14±0.40* | 2.24±0.42* | 1.97±0.38 | 8.91 | <0.001 |
| FVC (L) | 2.93±0.52 | 3.00±0.54 | 2.86±0.51 | 1.96 | 0.142 |
| FEV1/FVC (%) | 73.02±4.31* | 74.73±4.51* | 68.91±4.42 | 14.01 | <0.001 |
Tab.2 Comparison of lung function among the 3 groups of patients (Mean±SD)
| Time point/Variable | Baduanjin group (n=108) | Bedside cycle ergometer training group (n=109) | Balloon-blowing training group (n=117) | F | P |
|---|---|---|---|---|---|
| Postoperative day 1 | |||||
| FEV1 (L) | 1.52±0.31 | 1.49±0.33 | 1.51±0.32 | 0.21 | 0.812 |
| FVC (L) | 2.18±0.41 | 2.15±0.43 | 2.17±0.42 | 0.15 | 0.861 |
| FEV1/FVC (%) | 69.81±5.20 | 69.33±5.52 | 69.60±5.29 | 0.24 | 0.787 |
| Postoperative 4 weeks | |||||
| FEV1 (L) | 1.78±0.33 | 1.85±0.35* | 1.71±0.32 | 4.12 | 0.017 |
| FVC (L) | 2.52±0.45 | 2.58±0.47 | 2.48±0.44 | 1.45 | 0.236 |
| FEV1/FVC (%) | 70.62±4.81 | 71.70±5.11* | 68.94±4.92 | 3.78 | 0.024 |
| Postoperative 12 weeks | |||||
| FEV1 (L) | 2.05±0.38* | 2.15±0.40* | 1.92±0.36 | 9.85 | <0.001 |
| FVC (L) | 2.85±0.50 | 2.91±0.52 | 2.79±0.49 | 1.92 | 0.148 |
| FEV1/FVC (%) | 71.90±4.51* | 73.79±4.70* | 68.84±4.62 | 12.34 | <0.001 |
| Postoperative six months | |||||
| FEV1 (L) | 2.11±0.39* | 2.21±0.41* | 1.98±0.37 | 8.15 | <0.001 |
| FVC (L) | 2.90±0.51 | 2.96±0.53 | 2.85±0.50 | 1.79 | 0.168 |
| FEV1/FVC (%) | 72.82±4.41* | 74.50±4.63* | 69.52±4.48 | 12.28 | <0.001 |
| Postoperative one year | |||||
| FEV1 (L) | 2.14±0.40* | 2.24±0.42* | 1.97±0.38 | 8.91 | <0.001 |
| FVC (L) | 2.93±0.52 | 3.00±0.54 | 2.86±0.51 | 1.96 | 0.142 |
| FEV1/FVC (%) | 73.02±4.31* | 74.73±4.51* | 68.91±4.42 | 14.01 | <0.001 |
| Time point | Baduanjin group (n=108) | Bedside cycle ergometer training group (n=109) | Balloon-blowing training group (n=117) | F | P |
|---|---|---|---|---|---|
| Postoperative day 1 | 352.62±42.50 | 348.91±43.23 | 350.80±41.85 | 0.18 | 0.837 |
| Postoperative 4 weeks | 408.50±46.31 | 418.17±47.82* | 397.14±45.51 | 3.42 | 0.034 |
| Postoperative 12 weeks | 452.63±49.14* | 468.42±50.69* | 442.32±48.24 | 4.86 | 0.008 |
| Postoperative 6 months | 457.20±49.31* | 470.82±50.90* | 445.13±48.72 | 5.31 | 0.005 |
| Postoperative 1 year | 460.53±48.81* | 476.79±50.51* | 448.90±47.63 | 5.12 | 0.006 |
Tab.3 Comparison of exercise endurance among the 3 groups of patients (Mean±SD)
| Time point | Baduanjin group (n=108) | Bedside cycle ergometer training group (n=109) | Balloon-blowing training group (n=117) | F | P |
|---|---|---|---|---|---|
| Postoperative day 1 | 352.62±42.50 | 348.91±43.23 | 350.80±41.85 | 0.18 | 0.837 |
| Postoperative 4 weeks | 408.50±46.31 | 418.17±47.82* | 397.14±45.51 | 3.42 | 0.034 |
| Postoperative 12 weeks | 452.63±49.14* | 468.42±50.69* | 442.32±48.24 | 4.86 | 0.008 |
| Postoperative 6 months | 457.20±49.31* | 470.82±50.90* | 445.13±48.72 | 5.31 | 0.005 |
| Postoperative 1 year | 460.53±48.81* | 476.79±50.51* | 448.90±47.63 | 5.12 | 0.006 |
| Time point | Baduanjin group (n=108) | Bedside cycle ergometer training group (n=109) | Balloon-blowing training group (n=117) | F | P |
|---|---|---|---|---|---|
| Postoperative day 1 | 5.24±1.31 | 5.30±1.40 | 5.40±1.31 | 0.45 | 0.639 |
| Postoperative 4 weeks | 2.93±1.10*△ | 3.23±1.24 | 3.62±1.29 | 4.32 | 0.014 |
| Postoperative 12 weeks | 1.64±0.93*△ | 2.09±1.04* | 2.61±1.13 | 5.87 | 0.003 |
| Postoperative 6 months | 1.49±0.80*△ | 2.04±0.92* | 2.49±1.02 | 5.43 | 0.005 |
| Postoperative 1 year | 1.38±0.79*△ | 1.87±0.91* | 2.42±1.04 | 5.12 | 0.006 |
Tab.4 Comparison of dyspnea severity among the 3 groups of patients (Mean±SD)
| Time point | Baduanjin group (n=108) | Bedside cycle ergometer training group (n=109) | Balloon-blowing training group (n=117) | F | P |
|---|---|---|---|---|---|
| Postoperative day 1 | 5.24±1.31 | 5.30±1.40 | 5.40±1.31 | 0.45 | 0.639 |
| Postoperative 4 weeks | 2.93±1.10*△ | 3.23±1.24 | 3.62±1.29 | 4.32 | 0.014 |
| Postoperative 12 weeks | 1.64±0.93*△ | 2.09±1.04* | 2.61±1.13 | 5.87 | 0.003 |
| Postoperative 6 months | 1.49±0.80*△ | 2.04±0.92* | 2.49±1.02 | 5.43 | 0.005 |
| Postoperative 1 year | 1.38±0.79*△ | 1.87±0.91* | 2.42±1.04 | 5.12 | 0.006 |
| Time point | Baduanjin group (n=108) | Bedside cycle ergometer training group (n=109) | Balloon-blowing training group (n=117) | F | P |
|---|---|---|---|---|---|
| Postoperative day 1 | 4.65±1.05 | 4.72±1.12 | 4.68±1.08 | 0.11 | 0.896 |
| Postoperative 4 weeks | 2.52±0.88* | 2.95±0.96 | 3.28±1.04 | 5.82 | 0.003 |
| Postoperative 12 weeks | 1.35±0.66*△ | 1.88±0.79* | 2.47±0.92 | 9.76 | <0.001 |
| Postoperative 6 months | 1.26±0.64*△ | 1.80±0.77* | 2.41±0.90 | 9.24 | <0.001 |
| Postoperative 1 year | 1.18±0.61*△ | 1.72±0.75* | 2.35±0.88 | 8.93 | <0.001 |
Tab.5 Comparison of pain severity among the 3 groups of patients (Mean±SD)
| Time point | Baduanjin group (n=108) | Bedside cycle ergometer training group (n=109) | Balloon-blowing training group (n=117) | F | P |
|---|---|---|---|---|---|
| Postoperative day 1 | 4.65±1.05 | 4.72±1.12 | 4.68±1.08 | 0.11 | 0.896 |
| Postoperative 4 weeks | 2.52±0.88* | 2.95±0.96 | 3.28±1.04 | 5.82 | 0.003 |
| Postoperative 12 weeks | 1.35±0.66*△ | 1.88±0.79* | 2.47±0.92 | 9.76 | <0.001 |
| Postoperative 6 months | 1.26±0.64*△ | 1.80±0.77* | 2.41±0.90 | 9.24 | <0.001 |
| Postoperative 1 year | 1.18±0.61*△ | 1.72±0.75* | 2.35±0.88 | 8.93 | <0.001 |
| Time point | Baduanjin group (n=108) | Bedside cycle ergometer training group (n=109) | Balloon-blowing training group (n=117) | F | P |
|---|---|---|---|---|---|
| Postoperative day 1 | |||||
| CD4+/CD8+ | 1.15±0.28 | 1.12±0.30 | 1.14±0.29 | 0.32 | 0.726 |
| IgA (g/L) | 1.92±0.45 | 1.88±0.47 | 1.90±0.46 | 0.25 | 0.779 |
| IgG (g/L) | 10.35±2.15 | 10.28±2.20 | 10.32±2.18 | 0.04 | 0.961 |
| Postoperative 4 weeks | |||||
| CD4+/CD8+ | 1.38±0.31* | 1.25±0.29 | 1.18±0.28 | 4.25 | 0.015 |
| IgA (g/L) | 2.18±0.43* | 2.05±0.41 | 1.92±0.39 | 3.98 | 0.020 |
| IgG (g/L) | 11.45±2.10* | 10.95±2.06 | 10.65±2.04 | 3.72 | 0.025 |
| Postoperative 12 weeks | |||||
| CD4+/CD8+ | 1.58±0.33*△ | 1.38±0.31* | 1.22±0.29 | 4.85 | 0.008 |
| IgA (g/L) | 2.48±0.45* | 2.22±0.43 | 2.05±0.41 | 4.52 | 0.012 |
| IgG (g/L) | 12.55±2.15*△ | 11.55±2.09* | 11.05±2.06 | 4.28 | 0.015 |
| Postoperative 6 months | |||||
| CD4+/CD8+ | 1.56±0.32*△ | 1.36±0.30* | 1.21±0.28 | 4.72 | 0.009 |
| IgA (g/L) | 2.46±0.44* | 2.20±0.42 | 2.03±0.40 | 4.41 | 0.013 |
| IgG (g/L) | 12.45±2.14*△ | 11.48±2.07* | 11.00±2.05 | 4.20 | 0.016 |
| Postoperative 1 year | |||||
| CD4+/CD8+ | 1.55±0.32*△ | 1.35±0.30* | 1.20±0.28 | 4.65 | 0.010 |
| IgA (g/L) | 2.45±0.44* | 2.18±0.42 | 2.02±0.40 | 4.35 | 0.014 |
| IgG (g/L) | 12.35±2.13*△ | 11.42±2.08* | 10.95±2.05 | 4.12 | 0.017 |
Tab.6 Comparison of immune function among the 3 groups of patients (Mean±SD)
| Time point | Baduanjin group (n=108) | Bedside cycle ergometer training group (n=109) | Balloon-blowing training group (n=117) | F | P |
|---|---|---|---|---|---|
| Postoperative day 1 | |||||
| CD4+/CD8+ | 1.15±0.28 | 1.12±0.30 | 1.14±0.29 | 0.32 | 0.726 |
| IgA (g/L) | 1.92±0.45 | 1.88±0.47 | 1.90±0.46 | 0.25 | 0.779 |
| IgG (g/L) | 10.35±2.15 | 10.28±2.20 | 10.32±2.18 | 0.04 | 0.961 |
| Postoperative 4 weeks | |||||
| CD4+/CD8+ | 1.38±0.31* | 1.25±0.29 | 1.18±0.28 | 4.25 | 0.015 |
| IgA (g/L) | 2.18±0.43* | 2.05±0.41 | 1.92±0.39 | 3.98 | 0.020 |
| IgG (g/L) | 11.45±2.10* | 10.95±2.06 | 10.65±2.04 | 3.72 | 0.025 |
| Postoperative 12 weeks | |||||
| CD4+/CD8+ | 1.58±0.33*△ | 1.38±0.31* | 1.22±0.29 | 4.85 | 0.008 |
| IgA (g/L) | 2.48±0.45* | 2.22±0.43 | 2.05±0.41 | 4.52 | 0.012 |
| IgG (g/L) | 12.55±2.15*△ | 11.55±2.09* | 11.05±2.06 | 4.28 | 0.015 |
| Postoperative 6 months | |||||
| CD4+/CD8+ | 1.56±0.32*△ | 1.36±0.30* | 1.21±0.28 | 4.72 | 0.009 |
| IgA (g/L) | 2.46±0.44* | 2.20±0.42 | 2.03±0.40 | 4.41 | 0.013 |
| IgG (g/L) | 12.45±2.14*△ | 11.48±2.07* | 11.00±2.05 | 4.20 | 0.016 |
| Postoperative 1 year | |||||
| CD4+/CD8+ | 1.55±0.32*△ | 1.35±0.30* | 1.20±0.28 | 4.65 | 0.010 |
| IgA (g/L) | 2.45±0.44* | 2.18±0.42 | 2.02±0.40 | 4.35 | 0.014 |
| IgG (g/L) | 12.35±2.13*△ | 11.42±2.08* | 10.95±2.05 | 4.12 | 0.017 |
| Time point | Baduanjin group (n=108) | Bedside cycle ergometer training group (n=109) | Balloon-blowing training group (n=117) | F | P |
|---|---|---|---|---|---|
| Postoperative day 1 | 0.98±0.25 | 1.02±0.27 | 1.00±0.26 | 0.42 | 0.657 |
| Postoperative 4 weeks | 1.22±0.28 | 1.45±0.31* | 1.15±0.27 | 3.12 | 0.045 |
| Postoperative 12 weeks | 1.45±0.32* | 1.72±0.35*△ | 1.25±0.30 | 4.35 | 0.013 |
| Postoperative 6 months | 1.46±0.31* | 1.73±0.34*△ | 1.26±0.29 | 4.26 | 0.015 |
| Postoperative 1 year | 1.48±0.31* | 1.75±0.34*△ | 1.28±0.29 | 4.18 | 0.016 |
Tab.7 Comparison of aerobic capacity among the 3 groups of patients (Mean±SD)
| Time point | Baduanjin group (n=108) | Bedside cycle ergometer training group (n=109) | Balloon-blowing training group (n=117) | F | P |
|---|---|---|---|---|---|
| Postoperative day 1 | 0.98±0.25 | 1.02±0.27 | 1.00±0.26 | 0.42 | 0.657 |
| Postoperative 4 weeks | 1.22±0.28 | 1.45±0.31* | 1.15±0.27 | 3.12 | 0.045 |
| Postoperative 12 weeks | 1.45±0.32* | 1.72±0.35*△ | 1.25±0.30 | 4.35 | 0.013 |
| Postoperative 6 months | 1.46±0.31* | 1.73±0.34*△ | 1.26±0.29 | 4.26 | 0.015 |
| Postoperative 1 year | 1.48±0.31* | 1.75±0.34*△ | 1.28±0.29 | 4.18 | 0.016 |
| Time point | Baduanjin group (n=108) | Bedside cycle ergometer training group (n=109) | Balloon-blowing training group (n=117) | F | P |
|---|---|---|---|---|---|
| Postoperative day 1 | 58.34±8.51 | 57.93±8.80 | 58.12±8.56 | 0.07 | 0.933 |
| Postoperative 4 weeks | 72.63±9.19* | 68.50±9.04 | 65.84±8.90 | 4.85 | 0.008 |
| Postoperative 12 weeks | 85.41±8.80*△ | 78.93±9.08* | 73.53±9.31 | 9.63 | <0.001 |
| Postoperative 6 months | 85.83±8.62*△ | 79.14±9.04* | 73.76±9.10 | 9.85 | <0.001 |
| Postoperative 1 year | 86.24±8.50*△ | 79.33±8.92* | 74.14±9.22 | 10.25 | <0.001 |
Tab.8 Comparison of quality of life among the 3 groups of patients (Mean±SD)
| Time point | Baduanjin group (n=108) | Bedside cycle ergometer training group (n=109) | Balloon-blowing training group (n=117) | F | P |
|---|---|---|---|---|---|
| Postoperative day 1 | 58.34±8.51 | 57.93±8.80 | 58.12±8.56 | 0.07 | 0.933 |
| Postoperative 4 weeks | 72.63±9.19* | 68.50±9.04 | 65.84±8.90 | 4.85 | 0.008 |
| Postoperative 12 weeks | 85.41±8.80*△ | 78.93±9.08* | 73.53±9.31 | 9.63 | <0.001 |
| Postoperative 6 months | 85.83±8.62*△ | 79.14±9.04* | 73.76±9.10 | 9.85 | <0.001 |
| Postoperative 1 year | 86.24±8.50*△ | 79.33±8.92* | 74.14±9.22 | 10.25 | <0.001 |
| Time point | Baduanjin group (n=108) | Bedside cycle ergometer training group (n=109) | Balloon-blowing training group (n=117) | F | P |
|---|---|---|---|---|---|
| Postoperative 4 weeks | 92.50±6.81*△ | 85.32±9.21 | 78.61±11.50 | 8.95 | <0.001 |
| Postoperative 12 weeks | 88.69±8.22*△ | 79.23±10.57* | 72.44±13.82 | 12.34 | <0.001 |
| Postoperative 6 months | 87.52±8.91*△ | 78.04±11.50* | 70.91±14.48 | 11.62 | <0.001 |
| Postoperative 1 year | 86.34±9.50*△ | 76.82±12.33* | 69.54±15.23 | 10.87 | <0.001 |
Tab.9 Comparison of participation among the 3 groups of patients (Mean±SD)
| Time point | Baduanjin group (n=108) | Bedside cycle ergometer training group (n=109) | Balloon-blowing training group (n=117) | F | P |
|---|---|---|---|---|---|
| Postoperative 4 weeks | 92.50±6.81*△ | 85.32±9.21 | 78.61±11.50 | 8.95 | <0.001 |
| Postoperative 12 weeks | 88.69±8.22*△ | 79.23±10.57* | 72.44±13.82 | 12.34 | <0.001 |
| Postoperative 6 months | 87.52±8.91*△ | 78.04±11.50* | 70.91±14.48 | 11.62 | <0.001 |
| Postoperative 1 year | 86.34±9.50*△ | 76.82±12.33* | 69.54±15.23 | 10.87 | <0.001 |
| [1] | Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-63. doi:10.3322/caac.21834 |
| [2] | Yan TD, Black D, Bannon PG, et al. Systematic review and meta-analysis of randomized and nonrandomized trials on safety and efficacy of video-assisted thoracic surgery lobectomy for early-stage non-small-cell lung cancer[J]. J Clin Oncol, 2009, 27(15): 2553-62. doi:10.1200/jco.2008.18.2733 |
| [3] | Hong Q, Wang Y, Ma FY, et al. Patient-reported outcomes after lobectomy vs. segmentectomy for early-stage non-small cell lung cancer[J]. Surg Endosc, 2025, 39(11): 7566-75. doi:10.1007/s00464-025-12172-8 |
| [4] | 赖玉田, 王 娇, 李晓鸥, 等. 肺癌围手术期肺康复训练中国专家共识[J]. 中国肺癌杂志, 2024, 27(7): 495-503. |
| [5] | Xu JL, Li X, Zeng J, et al. Effect of Baduanjin Qigong on postoperative pulmonary rehabilitation in patients with non-small cell lung cancer: a randomized controlled trial[J]. Support Care Cancer, 2023, 32(1): 73. doi:10.1007/s00520-023-08194-4 |
| [6] | Oeser A, Messer S, Wagner C, et al. Cardiovascular training versus resistance training for fatigue in people with cancer[J]. Cochrane Database Syst Rev, 2024, 9(9): CD015519. doi:10.1002/14651858.cd015519.pub2 |
| [7] | 白 欢, 李 晶. 吹气球呼吸功能训练对肺癌患者术后康复效果及引流时间、引流量影响[J]. 医学食疗与健康, 2021, 19(10): 201-2. |
| [8] | Chen Y, Zhang P, Dong ZM, et al. Effect of Baduanjin exercise on health and functional status in patients with chronic obstructive pulmonary disease: a community-based, cluster-randomized controlled trial[J]. npj Prim Care Respir Med, 2024, 34: 43. doi:10.1038/s41533-024-00400-y |
| [9] | Ahmad AM, Abusarea SA, Fouad BZ, et al. Effect of adding early bedside cycling to inpatient cardiac rehabilitation on physical function and length of stay after heart valve surgery: a randomized controlled trial[J]. Arch Phys Med Rehabil, 2024, 105(6): 1050-7. doi:10.1016/j.apmr.2024.02.711 |
| [10] | 李景峰, 蒋天赐. 吹气球呼吸功能训练对肺癌患者术后肺功能及并发症的影响[J]. 深圳中西医结合杂志, 2023, 33(3): 119-22. |
| [11] | 国家体育总局健身气功管理中心. 健身气功·八段锦[M]. 北京: 人民体育出版社, 2003. |
| [12] | Scherr J, Wolfarth B, Christle JW, et al. Associations between Borg's rating of perceived exertion and physiological measures of exercise intensity[J]. Eur J Appl Physiol, 2013, 113(1): 147-55. doi:10.1007/s00421-012-2421-x |
| [13] | Zink EK, Kumble S, Beier M, et al. Physiological responses to in-bed cycle ergometry treatment in intensive care unit patients with external ventricular drainage[J]. Neurocritical Care, 2021, 35(3): 707-13. doi:10.1007/s12028-021-01204-5 |
| [14] | 刘国芳. 腹式呼吸训练+吹气球在哮喘慢性持续期患者康复护理中的应用[J]. 黑龙江医学, 2022, 46(20): 2518-20. |
| [15] | Heinicke G, Clay R, DeCato TW. Six-minute-walk testing[J]. Am J Respir Crit Care Med, 2021, 204(3): P5-6. doi:10.1164/rccm.2043p5 |
| [16] | Kendrick KR, Baxi SC, Smith RM. Usefulness of the modified 0-10 Borg scale in assessing the degree of dyspnea in patients with COPD and asthma[J]. J Emerg Nurs, 2000, 26(3): 216-22. doi:10.1016/s0099-1767(00)90093-x |
| [17] | Jensen MP, Chen C, Brugger AM. Interpretation of visual analog scale ratings and change scores: a reanalysis of two clinical trials of postoperative pain[J]. J Pain, 2003, 4(7): 407-14. doi:10.1016/s1526-5900(03)00716-8 |
| [18] | Jones LW, Watson D, Herndon II JE, et al. Peak oxygen consumption and long-term all-cause mortality in nonsmall cell lung cancer[J]. Cancer, 2010, 116(20): 4825-32. doi:10.1002/cncr.25396 |
| [19] | 李 鲁, 王红妹, 沈 毅. SF-36健康调查量表中文版的研制及其性能测试[J]. 中华预防医学杂志, 2002, 36(2): 109-13. doi:10.3760/j:issn:0253-9624.2002.02.011 |
| [20] | Ma JL, Li XY, Zhao SF, et al. Robot-assisted thoracic surgery versus video-assisted thoracic surgery for lung lobectomy or segmentectomy in patients with non-small cell lung cancer: a meta-analysis[J]. BMC Cancer, 2021, 21(1): 498. doi:10.1186/s12885-021-08241-5 |
| [21] | Cavalheri V, Burtin C, Formico VR, et al. Exercise training undertaken by people within 12 months of lung resection for non-small cell lung cancer[J]. Cochrane Database Syst Rev, 2019, 6(6): CD009955. doi:10.1002/14651858.cd009955.pub3 |
| [22] | Cavalheri V, Granger CL. Exercise training as part of lung cancer therapy[J]. Respirology, 2020, 25(S2): 80-7. doi:10.1111/resp.13869 |
| [23] | Abidi Y, Fekete M, Farkas Á, et al. Effectiveness and quality of life in lung cancer, pre-, post- and perioperative rehabilitation–A review[J]. PhysInt, 2023, 110(2): 89-107. doi:10.1556/2060.2023.00237 |
| [24] | Wu D, Li J, Dong H, et al. Effect of Baduanjin on postoperative activity tolerance, lung function and negative emotions in patients with lung cancer: a protocol for systematic review and meta-analysis[J]. BMJ Open, 2025,15(5): e093152. doi:10.1136/bmjopen-2024-093152 |
| [25] | Plinsinga ML, Singh B, Rose GL, et al. The effect of exercise on pain in people with cancer: a systematic review with meta-analysis[J]. Sports Med, 2023, 53(9): 1737-52. doi:10.1007/s40279-023-01862-9 |
| [26] | Wang X, Yin X, Liu P, et al. The effect of Baduanjin Qigong combined with five-elements music on anxiety and quality of sleep in asymptomatic patients with COVID-19 infection: a randomised controlled trial[J]. Heliyon, 2023, 9(8): e18962. doi:10.1016/j.heliyon.2023.e18962 |
| [27] | Oh B, Bae K, Lamoury G, et al. The effects of Tai Chi and Qigong on immune responses: a systematic review and meta-analysis[J]. Medicines, 2020, 7(7): 39. doi:10.3390/medicines7070039 |
| [28] | Scott JM, Thomas SM, Herndon JE 2nd, et al. Effects and tolerability of exercise therapy modality on cardiorespiratory fitness in lung cancer: a randomized controlled trial[J]. J Cachexia Sarcopenia Muscle, 2021, 12(6): 1456-65. doi:10.1002/jcsm.12828 |
| [29] | Sturzenegger N, Schneider SR, Furian M, et al. The effect of eccentric cycling on cerebral and muscle tissue oxygenation in patients with pulmonary hypertension and healthy individuals: a randomized controlled crossover trial[J]. J Clin Med, 2025, 14(16): 5751. doi:10.3390/jcm14165751 |
| [30] | Ulrich S, Kammerlander A, Schneider SR, et al. Effect of eccentric cycling on oxygen uptake and hemodynamics in patients with chronic obstructive pulmonary disease: a randomized controlled crossover trial[J]. Respiration, 2025, 104(9): 637-47. doi:10.1159/000545787 |
| [31] | Zisi D, Chryssanthopoulos C, Nanas S, et al. The effectiveness of the active cycle of breathing technique in patients with chronic respiratory diseases: a systematic review[J]. Heart Lung, 2022, 53: 89-98. doi:10.1016/j.hrtlng.2022.02.006 |
| [1] | Junyu DONG, Jiajun GUO, Dairong LI, Yonghong DU. Ultrasound-synergized targeted nanoparticles suppress proliferation, migration and invasion of hypoxic lung cancer cells in vitro [J]. Journal of Southern Medical University, 2026, 46(6): 1278-1289. |
| [2] | Zhiqing LIANG, Fuzhen PAN, Liqiang DENG, Zhefen MAI, Yun MA, Chuanjian SHI, Weiming FU. Shengmai San improves osimertinib resistance of non-small cell lung cancer cells by regulating the lactate/Wnt/β-catenin/LDHA pathway [J]. Journal of Southern Medical University, 2026, 46(3): 523-531. |
| [3] | Qizhi HUANG, Daipeng XIE, Lintong YAO, Qiaxuan LI, Shaowei WU, Haiyu ZHOU. Tumor microenvironment-specific CT radiomics signature for predicting immunotherapy response in non-small cell lung cancer [J]. Journal of Southern Medical University, 2025, 45(9): 1903-1918. |
| [4] | Lijun HE, Xiaofei CHEN, Chenxin YAN, Lin SHI. Inhibitory effect of Fuzheng Huaji Decoction against non-small cell lung cancer cells in vitro and the possible molecular mechanism [J]. Journal of Southern Medical University, 2025, 45(6): 1143-1152. |
| [5] | Xinheng WANG, Xiaohan SHAO, Tongtong LI, Lu ZHANG, Qinjun YANG, Weidong YE, Jiabing TONG, Zegeng LI, Xiangming FANG. Pingchuanning Formula suppresses airway inflammation in a rat model of asthmatic cold syndrome by regulating the HMGB1/Beclin-1 axis-mediated autophagy [J]. Journal of Southern Medical University, 2025, 45(6): 1153-1162. |
| [6] | Dandan LI, Jiaxin CHU, Yan YAN, Wenjun XU, Xingchun ZHU, Yun SUN, Haofeng DING, Li REN, Bo ZHU. Curcumin inhibits lipid metabolism in non-small cell lung cancer by downregulating the HIF-1α pathway [J]. Journal of Southern Medical University, 2025, 45(5): 1039-1046. |
| [7] | Na ZHONG, Huijie WANG, Wenying ZHAO, Zhengui SUN, Biao GENG. High RNF7 expression enhances PD-1 resistance of non-small cell lung cancer cells by promoting CXCL1 expression and myeloid-derived suppressor cell recruitment via activating NF-κB signaling [J]. Journal of Southern Medical University, 2024, 44(9): 1704-1711. |
| [8] | Guiling CHEN, Xiaofeng LIAO, Pengtao SUN, Huan CEN, Shengchun SHU, Bijing LI, Jinhua LI. Solasonine promotes apoptosis of non-small cell lung cancer cells by regulating the Bcl-2/Bax/caspase-3 pathway [J]. Journal of Southern Medical University, 2024, 44(6): 1109-1116. |
| [9] | Feifan LI, Junxin XIANG, Jiahui LIU, Xiaojing WANG, Hao JIANG. Overexpression of lncRNA FEZF1-AS1 promotes progression of non-small cell lung cancer via the miR-130a-5p/CCND1 axis [J]. Journal of Southern Medical University, 2024, 44(5): 841-850. |
| [10] | YANG Yang, LIU Gang, OU Yi, LU Wenqi. Lung-protective effect of esketamine combined with distal limb ischemic preconditioning in elderly patients undergoing thoracoscopic radical surgery for lung cancer: a randomized controlled trial in 160 cases [J]. Journal of Southern Medical University, 2024, 44(3): 484-490. |
| [11] | HAN Qiqi, YE Mengran, JIN Qili. Demethylzeylasteral inhibits proliferation, migration and invasion and promotes apoptosis of non-small cell lung cancer cells by inhibiting the AKT/CREB signaling pathway [J]. Journal of Southern Medical University, 2024, 44(2): 280-288. |
| [12] | Xuerou LIU, Yumei YANG, Wei LIU, Zhen ZHANG, Xingqi ZHOU, Wenyu XIE, Lin SHEN, Mengxiao ZHANG, Xian LI, Jialan ZANG, Shanshan LI. Euphorbia helioscopia inhibits proliferation, invasion, and migration and promotes apoptosis of non-small cell lung cancer cells [J]. Journal of Southern Medical University, 2024, 44(10): 1918-1925. |
| [13] | Yumei YANG, Xuerou LIU, Wei LIU, Xingqi ZHOU, Zhen ZHANG, Yan HU, Peipei LIU, Xian LI, Hao LIU, Shanshan LI. Aumolertinib combined with anlotinib inhibits proliferation of non-small cell lung cancer cells by down-regulating the PI3K/AKT pathway [J]. Journal of Southern Medical University, 2024, 44(10): 1965-1975. |
| [14] | Xirui FAN, Zhilin QI, Yuanjie DENG, Zihan YANG, Li SUN, Guohao LI, Juanjuan LIANG, Fei WU, Liwen YUAN. LncRNA MAGI2-AS3 enhances cisplatin sensitivity of non-small cell lung cancer cells by regulating the miR-1269a/PTEN/AKT pathway [J]. Journal of Southern Medical University, 2024, 44(10): 2033-2043. |
| [15] | XIE Ziping, LIU Liwei, FANG Jincun, ZHONG Xingyi, LIN Junhao, CHEN Fengsheng. ARHGAP21 inhibits epithelial-mesenchymal transition by inactivating the WNT signaling pathway in non-small cell lung cancer [J]. Journal of Southern Medical University, 2023, 43(8): 1322-1332. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||